



VERTOS *mild*® ONE-YEAR POST-STUDY FOLLOW-UP DATA
PUBLISHED IN PAIN PRACTICE JOURNAL

ALISO VIEJO, Calif. – July 11, 2011 –Medical device company [Vertos Medical Inc.](#) has announced that one-year post-study follow-up data on its *mild* procedure for lumbar spinal stenosis (LSS) have been published in the peer-reviewed journal Pain Practice. In “[Long Term Results of Percutaneous Lumbar Decompression *mild* for Spinal Stenosis](#),” authors concluded that the *mild* procedure is safe and provides long-term pain relief and improved mobility in patients with LSS.

The article reviews 12-month post-study follow-up data on 58 patients from the 11-center MiDAS I (*mild*® Decompression Alternative to Open Surgery) clinical trial. The authors found that *mild* patients continued to experience a statistically significant and clinically relevant reduction in pain and improvement in mobility at one year, according to a number of patient-reported outcomes measures. In addition, 74 percent of patients remained satisfied with the overall results of their *mild* procedure. No device or procedure-related serious adverse events were reported.

“These one-year findings are very positive news for both physicians and patients, as they demonstrate *mild*’s value as an early therapeutic option in the LSS treatment continuum,” said Nagy Mekhail, M.D. Ph.D., director of evidence-based pain management research at the Cleveland Clinic and lead author of the Pain Practice article. “Historically, LSS patients have had two primary treatment options: conservative care, which may generate either temporary or no response, or open surgical procedures, which carry a higher degree of risk. With *mild*, we have a safe, effective and lasting therapeutic alternative that finally fills the gap between these two options and addresses a significant unmet need in the management of patients with symptomatic spinal stenosis.”

Vertos previously announced the one-year *mild* post-study follow-up data at the annual Cleveland Clinic symposium on March 7, 2011. Since then, the data have been presented at a number of professional society meetings over the last several months, including the annual meetings of the American Academy of Pain Medicine, the American Society of Interventional Pain Physicians, and the West Virginia Society of Pain Physicians. At several of these meetings, *mild* research, including the one-year post-study follow-up data, has received top awards for scientific excellence.

“The Pain Practice article represents an important addition to the body of published, peer-reviewed research on *mild*. We are pleased about the growing recognition of the solid clinical evidence supporting the procedure,” said James M. Corbett, president and chief executive

officer of Vertos Medical. “The research, which now includes long-term data, has been a key driver of physician adoption and patient access to the *mild* procedure”

About *mild*

mild is an image-guided percutaneous (through the skin) decompression laminotomy procedure used to treat patients with LSS, a condition diagnosed in 1.2 million patients annually in the United States.¹ A less invasive alternative to open or endoscopic surgery, *mild* safely and therapeutically reduces pain and increases mobility while maintaining structural stability.

About Vertos Medical Inc.

Vertos Medical was founded to advance the treatment of patients suffering with lumbar spinal stenosis (LSS), a degenerative, age-related narrowing of the lower spinal canal. Its proprietary platform technologies include *mild*, which offers a therapeutic intervention to treat LSS and achieve lumbar spine decompression utilizing 3-D imaging. For more information, visit www.vertosmed.com.

* Vertos *mild* is FDA cleared for treating lumbar spinal stenosis.

¹ Derived from the Longitudinal Medicare Database.